Shares of Cell MedX Corp. (OTCMKTS:CMXC – Get Free Report) traded up 9.1% on Monday . The stock traded as high as $0.46 and last traded at $0.17. 1,934 shares traded hands during trading, a decline of 90% from the average session volume of 20,342 shares. The stock had previously closed at $0.15.
Cell MedX Stock Performance
The company has a 50-day moving average of $0.38 and a 200 day moving average of $0.21.
Cell MedX Company Profile
Cell MedX Corp., a biotech company, discovers, develops, and commercializes therapeutic and non-therapeutic products for patients with diabetes, Parkinson’s disease, high blood pressure, neuropathy, and kidney functions in the United States. The company develops and manufactures eBalance Pro System for professional use by healthcare practitioners in a clinical setting; and eBalance Home System for home use for general wellness and pain management treatment, which are controlled by the eBalance Console that acts as the central controller for three pre-programmed microcurrent algorithms, including wellness, pain management, and dual.
Featured Articles
- Five stocks we like better than Cell MedX
- 10 Best Airline Stocks to Buy
- Nebius Group: NVIDIA’s Investment Sparks All-Time Highs
- Insider Buying Explained: What Investors Need to Know
- SoFi Stock Rallying Strong in the Last 5 Days—What’s Driving It?
- How to Short a Stock in 5 Easy Steps
- Intel Surges on M&A Talks: Rally Beginning or Just a Headfake?
Receive News & Ratings for Cell MedX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cell MedX and related companies with MarketBeat.com's FREE daily email newsletter.
